PHAT — Phathom Pharmaceuticals Share Price
Last trade - 00:00- $567.12m
- $934.14m
- $175.11m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.75 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.37 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -23.93% | ||
| Return on Equity | n/a | ||
| Operating Margin | -17.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.68 | 55.25 | 175.11 | 314.71 | 488.68 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.
Directors
- Tadataka Yamada NEC (76)
- Terrie Curran PRE (52)
- Azmi Nabulsi CFD (61)
- David Socks CFD (46)
- Anthony Guzzo CFO
- Michael Cola IND (61)
- Heidi Kunz IND (67)
- Asit Parikh IND (49)
- Mark Stenhouse IND (54)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- January 9th, 2018
- Public Since
- October 25th, 2019
- No. of Shareholders
- 56
- No. of Employees
- 371
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 80,900,934
- Address
- 100 Campus Drive, Suite 102, FLORHAM PARK, 07932
- Web
- https://www.phathompharma.com/
- Phone
- +1 3026365400
- Auditors
- Ernst & Young LLP
Latest News for PHAT
Upcoming Events for PHAT
Q3 2026 Phathom Pharmaceuticals, Inc. Earnings Call
Q3 2026 Phathom Pharmaceuticals Inc Earnings Release
Q4 2026 Phathom Pharmaceuticals Inc Earnings Release
Similar to PHAT
Alkermes
NASDAQ Global Select Market
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 04:42 UTC, shares in Phathom Pharmaceuticals are trading at $7.01. This share price information is delayed by 15 minutes.
Shares in Phathom Pharmaceuticals last closed at $7.01 and the price had moved by -47.92% over the past 365 days. In terms of relative price strength the Phathom Pharmaceuticals share price has underperformed the S&P500 Index by -54.21% over the past year.
The overall consensus recommendation for Phathom Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePhathom Pharmaceuticals does not currently pay a dividend.
Phathom Pharmaceuticals does not currently pay a dividend.
Phathom Pharmaceuticals does not currently pay a dividend.
To buy shares in Phathom Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $7.01, shares in Phathom Pharmaceuticals had a market capitalisation of $567.12m.
Here are the trading details for Phathom Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PHAT
Based on an overall assessment of its quality, value and momentum Phathom Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Phathom Pharmaceuticals is $19.64. That is 180.17% above the last closing price of $7.01.
Analysts covering Phathom Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.79 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Phathom Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -43.91%.
As of the last closing price of $7.01, shares in Phathom Pharmaceuticals were trading -34.68% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Phathom Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 14.75. The shares last closed at $7.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Phathom Pharmaceuticals' management team is headed by:
- Tadataka Yamada - NEC
- Terrie Curran - PRE
- Azmi Nabulsi - CFD
- David Socks - CFD
- Anthony Guzzo - CFO
- Michael Cola - IND
- Heidi Kunz - IND
- Asit Parikh - IND
- Mark Stenhouse - IND